Long-Term Efficacy of Anti-Tumor Necrosis Factor Agents in Pediatric Luminal Crohn's Disease: A Systematic Review of Real-World Evidence Studies
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To determine the long-term efficacy of the anti-tumor necrosis factor (TNF) agents, infliximab (IFX) and adalimumab (ADA), in pediatric luminal Crohn's disease (CD) by performing a systematic literature review. Methods: An electronic search was performed in Medline, Embase, and the Cochrane Library from inception to September 26, 2019. Eligible studies were cohort studies with observation periods that exceeded 1 year. Studies that reported time-to-event analyses were included. Events were defined as discontinuation of anti-TNF therapy for secondary loss of response. We extracted the probabilities of continuing anti-TNF therapy 1, 2, and 3 years after initiation. Results: In total, 2,464 papers were screened, 94 were selected for full text review, and 13 studies (11 on IFX, 2 on ADA) met our eligibility criteria for inclusion. After 1 year, 83–97% of patients were still receiving IFX therapy. After 2 and 3 years the probability of continuing IFX therapy decreased to 67–91% and 61–85%, respectively. In total, 5 of the 11 studies subgrouped by concomitant medication consistently showed that the probabilities of continuing IFX therapy in patients with prolonged immunomodulator use were higher than those in patients on IFX monotherapy. Conclusion: This review of real-world evidence studies confirms the long-term therapeutic benefit of IFX therapy in diverse cohorts of children with luminal CD. Moreover, it supports the view that combination therapy with an immunomodulator prolongs the durability of IFX therapy in patients who previously failed to recover following first-line therapy. The limited number of time-to-event studies in patients on ADA prevented us from drawing definite conclusions about its long-term efficacy.
Abstract
Purpose: To determine the long-term efficacy of the anti-tumor necrosis factor (TNF) agents, infliximab (IFX) and adalimumab (ADA), in pediatric luminal Crohn's disease (CD) by performing a systematic literature review. Methods: An electronic search was performed in Medline, Embase, and the Cochrane Library from inception to September 26, 2019. Eligible studies were cohort studies with observation periods that exceeded 1 year. Studies that reported time-to-event analyses were included. Events were defined as discontinuation of anti-TNF therapy for secondary loss of response. We extracted the probabilities of continuing anti-TNF therapy 1, 2, and 3 years after initiation. Results: In total, 2,464 papers were screened, 94 were selected for full text review, and 13 studies (11 on IFX, 2 on ADA) met our eligibility criteria for inclusion. After 1 year, 83–97% of patients were still receiving IFX therapy. After 2 and 3 years the probability of continuing IFX therapy decreased to 67–91% and 61–85%, respectively. In total, 5 of the 11 studies subgrouped by concomitant medication consistently showed that the probabilities of continuing IFX therapy in patients with prolonged immunomodulator use were higher than those in patients on IFX monotherapy. Conclusion: This review of real-world evidence studies confirms the long-term therapeutic benefit of IFX therapy in diverse cohorts of children with luminal CD. Moreover, it supports the view that combination therapy with an immunomodulator prolongs the durability of IFX therapy in patients who previously failed to recover following first-line therapy. The limited number of time-to-event studies in patients on ADA prevented us from drawing definite conclusions about its long-term efficacy.
참고문헌 (24)
- Ruemmele FM, "Consensus guidelines of ECCO", ESPGHAN on the medical management of pediatric Crohn's disease, 2014, pp.8, 1179~1207
- Mack DR, "Canadian Association of Gastroenterology clinical practice guideline for the medical management of pediatric luminal Crohn's disease", Gastroenterology, 157, pp.320~348 (2019)
- Hyams J, "Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children", Gastroenterology, 132, pp.863~873 (2007)
- Hyams JS, "Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children", Gastroenterology, 143, pp.365~374 (2012)
- Bramer WM, "De-duplication of database search results for systematic reviews in EndNote", J Med Libr Assoc, 104, pp.240~243 (2016)
- Ouzzani M, "Rayyan-a web and mobile app for systematic reviews", Syst Rev, 5, pp.210~ (2016)
- Tierney JF, "Practical methods for incorporating summary time-to-event data into meta-analysis", Trials, 8, pp.16~ (2007)
- Hyams JS, "Long-term outcome of maintenance infliximab therapy in children with Crohn's disease", Inflamm Bowel Dis, 15, pp.816~822 (2009)
- de Bie CI, "The duration of effect of infliximab maintenance treatment in paediatric Crohn's disease is limited", Aliment Pharmacol Ther, 33, pp.243~250 (2011)
- Gouldthorpe O, "Loss of response to long-term infliximab therapy in children with Crohn's disease", Pharmaceuticals(Basel), 6, pp.1322~1334 (2013)
- Vahabnezhad E, "A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel disease", Inflamm Bowel Dis, 20, pp.606~613 (2014)
- Church PC, "Infliximab maintains durable response and facilitates catch-up growth in luminal pediatric Crohn's disease", Inflamm Bowel Dis, 20, pp.1177~1186 (2014)
- Grover Z, "Predictors of response to Infliximab in children with luminal Crohn's disease", J Crohn's Colitis, 8, pp.739~746 (2014)
- Grossi V, "Concomitant use of immunomodulators affects the durability of infliximab therapy in children with Crohn's disease", Clin Gastroenterol Hepatol, 13, pp.1748~1756 (2015)
- Lee YM, "Infliximab"top-down"strategy is superior to"step-up"in maintaining long-term remission in the treatment of pediatric crohn disease", J Pediatr Gastroenterol Nutr, 60, pp.737~743 (2015)
- Dupont-Lucas C, "Identifying patients at high risk of loss of response to infliximab maintenance therapy in paediatric Crohn's disease", J Crohn's Colitis, 10, pp.795~804 (2016)
- Cheng J, "Concomitant therapy with immunomodulator enhances infliximab durability in pediatric inflammatory bowel disease", Inflamm Bowel Dis, 23, pp.1762~1773 (2017)
- deBruyn JC, "Long-term outcomes of infliximab use for pediatric Crohn disease : a canadian multicenter clinical practice experience", J Pediatr Gastroenterol Nutr, 66, pp.268~273 (2018)
- Rosh JR, "Retrospective evaluation of the safety and effect of adalimumab therapy(RESEAT)in pediatric Crohn's disease", Am J Gastroenterol, 104, pp.3042~3049 (2009)
- Cozijnsen M, "Adalimumab therapy in children with Crohn disease previously treated with infliximab", J Pediatr Gastroenterol Nutr, 60, pp.205~210 (2015)
- Li S, "Efficacy and safety of infliximab in pediatric Crohn disease : a systematic review and meta-analysis", Can J Hosp Pharm, 72, pp.227~238 (2019)
- Dziechciarz P, "Efficacy and safety of adalimumab for paediatric Crohn's disease : a systematic review", J Crohn's Colitis, 10, pp.1237~1244 (2016)
- Assa A, "Proactive monitoring of adalimumab trough concentration associated with increased clinical remission in children with Crohn's disease compared with reactive monitoring", Gastroenterology, 157, pp.985~996 (2019)
- Frymoyer A, "Infliximab dosing strategies and predicted trough exposure in children with Crohn disease", J Pediatr Gastroenterol Nutr, 62, pp.723~727 (2016)